A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.

El-Khoueiry, A B

A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. [electronic resource] - Investigational new drugs Jun 2012 - 1175-83 p. digital

Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural

1573-0646

10.1007/s10637-011-9658-9 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Benzenesulfonates--administration & dosage
Cyclooxygenase 2--genetics
Cytidine Deaminase
Deoxycytidine--administration & dosage
Disease-Free Survival
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Niacinamide--analogs & derivatives
Nucleoside Deaminases--genetics
Pancreatic Neoplasms--drug therapy
Phenylurea Compounds
Polymorphism, Single Nucleotide
Pyridines--administration & dosage
Ribonucleoside Diphosphate Reductase
Sorafenib
Tumor Suppressor Proteins--genetics
Gemcitabine